SS
Highly rated in
1
conditions

Simiso M. Sokhela

Wits RHI Yeoville Clinic
Johannesburg, GT
Highly rated in
1
conditions
Clinical Trials:Currently Recruiting for 4 Trials
Highly rated in
1
conditions
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Simiso M. Sokhela's experience treating your condition:
About Simiso M. Sokhela

Simiso Sokhela practices in Johannesburg, South Africa. Sokhela is highly rated in 1 condition, according to our data. Their top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Obesity, and COVID-19.

Their clinical research consists of co-authoring 23 peer reviewed articles and participating in 8 clinical trials in the past 15 years.

Locations
Johannesburg, GT, ZA
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials
This is a Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety, and Tolerability of Molnupiravir 800 mg Administered 12-hourly for Five Days to Adult Patients With Mild COVID-19 at the Time of Enrolment Who Are at Risk of Progression to Severe Disease, Compared to a Placebo. Patients With Recent Onset of COVID-19 Symptoms Will be Screened to Assess Eligibility for Enrolment. Confirmation of SARS-CoV-2 Infection Will be Performed Through Rapid Antigen Detection Using the LumiraDx Point of Care Diagnostic Platform.
Enrollment Status: Recruiting
Publish Date: August 16, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Cross-sectional, Observational Study to Characterise Long-COVID in an Urban Sample of South African Adults
Enrollment Status: Recruiting
Publish Date: August 11, 2022
A Single Arm, Phase 3 Study, Exploring the Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV, a Pilot Switch Study Strategy in South Africa
Enrollment Status: Recruiting
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drug: Doravirine+Lamivudine+Tenofovir Disoproxil Fumarate
Study Phase: Phase 3
ADORE: A Single-arm, Phase 3, Pilot Study Investigating the Efficacy of Doravirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With Non-nucleoside Reverse Transcriptase Inhibitor Resistance
Enrollment Status: Recruiting
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drug: Doravirine+Lamivudine+Tenofovir
Study Phase: Phase 3
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: DolutegravirTenofovir AlafenamideTruvadaAtripla
Study Phase: Phase 3
A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)
Enrollment Status: Completed
Publish Date: July 14, 2022
Intervention Type: Drug
Study Drug: DuACT
Study Phase: Phase 2
The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: NitazoxanideSofosbuvir/Daclatasvir
Study Phase: Phase 2
View 4 Less Clinical Trials -
23 Total Publications
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.
Journal: AIDS (London, England)
Published: September 29, 2022
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more